Geneva, 19 September 2014 – Zimbabweans stand to gain access to better medicines after the World Health Organization’s (WHO’s) approval, this week, of a medicines quality control laboratory in Harare. The approval, which follows a thorough assessment by WHO, means that the laboratory operates in compliance with international standards and can carry out quality tests on medicines purchased by the Global Fund to Fight AIDS, TB and Malaria as well as by other large purchasers of medicines for developing countries, such as UNICEF.
Medicines and medical device donation guidelines
With early diagnosis and correct treatment, patients infected with Ebola have a good chance of survival. With proper precautions, the risk of Ebola spreading can be mitigated. Early diagnosis, treatment and containment require medicines and medical devices which can be of limited supply in countries with scarce resources. The Department of Essential Medicines an Health Products will be providing information resources as they become available, to meet the medical product needs for the Ebola response.
New study shows better use of medicines in countries adopting WHO ‘essential medicines’ policies
The wrong use of medicines is a threat to patients’ health and a global public health problem. The consequences of over- or under-using medicines can result in serious negative drug reactions, sometimes leading to death, drug resistance and a waste of financial resources. The World Health Organization (WHO) has advocated the essential medicines model since 1978 and has developed a range of policies to promote good use of medicines. A study published in PLoS reveals that policies recommended by WHO promote better use of medicines and therefore better patient outcomes and significant cost savings in a number of low-income countries.
After 2 days of discussion on potential Ebola therapies and vaccines, more than 150 participants, representing the fields of research and clinical investigation, ethics, legal, regulatory, financing, and data collection, identified several therapeutic and vaccine interventions that should be the focus of priority clinical evaluation at this time.
Essential Medicines and Health Products (EMP)
Our vision is that people everywhere have access to the essential medicines and health products they need; that the medicines and health products are safe, effective and of assured quality; and that medicines are prescribed and used rationally and that medical devices are used and managed effectively.
Visit "'About us'" to learn more.